Substantial challenges characterise the management of chronic obstructive pulmonary disease (COPD), including a progressively ...

Dupilumab reduces COPD exacerbations and Type 2 inflammation biomarkers, with strongest benefit in patients with high ...

Dupilumab in combination with other biologic agents is safe and effective for treating various chronic inflammatory conditions.

[A]lthough our findings found that there is insufficient evidence to suggest that dupilumab use is associated with joint pain, the prevalence of joint pain observed among patients treated with ...

Patients with asthma and allergic bronchopulmonary aspergillosis experienced improvements with dupilumab, according to data ...

Treatment with dupilumab is associated with weight gain in about two thirds of adults with atopic dermatitis over 3-6 months, according to a retrospective study.

Discover a study that highlights dupilumab’s consistent efficacy in eosinophilic oesophagitis, even among patients with ...

Dupilumab, a fully human monoclonal antibody that blocks interleukin-4 and interleukin-13, has shown efficacy in patients with asthma and elevated eosinophil levels. The blockade by dupilumab of th ...

Dupilumab (Dupixent; Sanofi/Regeneron) has been approved to treat moderate to severe AD in children aged 6 months and older as well as in children who have asthma and eosinophilic esophagitis.

Dupilumab, a fully human monoclonal antibody that blocks the interleukin-4 and interleukin-13 pathways, is approved for the treatment of five diseases marked by type 2 inflammation that are often ...

Since its release in 2017, dupilumab (a fully humanized monoclonal antibody that blocks IL-4 and IL-13) has transformed the therapeutic landscape for managing atopic dermatitis (AD) and other ...

Dupilumab (Dupixent), a medicine that you get as a shot, is the first new treatment for CSU in the U.S. in over a decade. It’s already used to treat different inflammation conditions in the U.S ...